Tumor Markers and Their Importance in Glioblastoma Diagnosis and Treatment
Main Article Content
Abstract
Glioblastoma is the most common and most aggressive tumor of the central nervous system whose morbidity and mortality remain very high despite all types of treatment (surgical resection, local and systemic chemotherapy). Numerous associated molecular alterations have been reported, but only a few are associated with survival. Despite several investigations and discoveries about this pathology, the survival rate is still very low. However, tumor markers are not currently taken much into account and these are often of importance as they can see the cause and even predict or diagnose early. The purpose of this research is to show the importance of glioblastoma tumor markers as part of the diagnosis of this disease, and also how they influence the choice of treatment, since, according to molecular genetics, according to the results found in this research, there are a variety of markers that increase helping us to identify the pathology and at the same time, if neutralized, can help favorably to the treatment and prognosis of the patient. Such is the case of the YKL40 marker, LRP, RAP, ApoE3, GOLM1, TROY and angiopep-2.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Javath-Hussain, S., Selvaraj, J., Mohanty-Mohapatra, M., & Rajendiran, S.. (2019, August). Clinical utility of pleural fluid YKL-40 as a marker of malignant pleural effusion. Current Problems in Cancer, 43, pp.354-362.
II. Hung, A., Garzon-Muvdi, T., & Lim, M.. (2017, June). Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurgery, 102, pp.494-506.
III. Raucher, D.. (2019, February 15). Tumor targeting peptides: novel therapeutic strategies in glioblastoma. Current Opinion in Pharmacology, 47, pp.14-19.
IV. Singh, A., Srivastava, N., Yadav, A., & Ateeq, B.. (2020, October). Targeting AGTR1/NF-jB/CXCR4 axis by miR-155 attenuates oncogenesis in glioblastoma. Neoplasia, 22, p.497-510.
V. Tsuji, S., Ohno, Y., Nakamura, S., Yamada, T., Noda, Y., Saio, M., Iwama, T., Shimazawa, M., & Hara, H.. (2019, November 15). Temozolomide has anti-tumor effects through the phosphorylation of cPLA2 on glioblastoma cells. Brain Research, 1723, 146396.
VI. Ding, X., Deng, G., Liu, J., Liu, B., Yuen, F., Yang, X, & Chen, Q. (2019, March 19). GOLM1 silencing inhibits the proliferation and motility of human glioblastoma cells via the Wnt/β-catenin signaling pathway. Brain Research, 1717, pp.117-126.
VII. Zhou, Y., Wu, W., Bi, H., Yang, D., & Zhang, C.. (2020, January 23). Glioblastoma precision therapy: From the bench to the clinic. Cancer Letters, 475, pp.79-91.
VIII. Lee, E., L-Yong, R., Paddison, P., & Zhu, J.. (2018, January 19). Comparison of glioblastoma (GBM) molecular classification methods. Seminars in Cancer Biology, 53, pp.201-211.
IX. Tompa, M., Nagy, A., Komoly, S., & Kalman, B. (2019, May 7). Wnt pathway markers in molecular subgroups of glioblastoma. Brain Research, 1718, pp.114-125.
X. Ding, Z., M-Kloss, J., Tuncali, S., L-Tran, N., & C-Loftus, J.. (2020, September). TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance. Neoplasia, 22, pp.352-364.
XI. Neurología elemental, Fermando Barinagarrementeria, Luis Dávila, Minerva López, 2nd edition, ELSEVIER, Neurooncología, chapter 38.
XII. Manual de Oncología, 6th edition, Ángel Herrera-Gómez, Silvio A. Ñamendys-Silva, Abelardo Meneses-García, part V, chapter 29.
XIII. Adams and Victor. Principles of Neurology, 11th edition, Allan H. Ropper, Martin A. Samuels, Joshua P. Klein, Sashank Prasad, Chapter 30.